Welcome to our dedicated page for Mirum Pharmaceuticals news (Ticker: MIRM), a resource for investors and traders seeking the latest updates and insights on Mirum Pharmaceuticals stock.
Mirum Pharmaceuticals, Inc. develops and commercializes medicines for rare diseases, with recurring updates centered on product sales, clinical readouts, regulatory interactions and employee equity grants. The company’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome and progressive familial intrahepatic cholestasis, CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis.
News about MIRM also covers clinical-stage programs including volixibat, an IBAT inhibitor for primary sclerosing cholangitis and primary biliary cholangitis; brelovitug, a monoclonal antibody designed to bind hepatitis B surface antigen for chronic hepatitis delta virus; and MRM-3379, a PDE4D inhibitor for Fragile X syndrome. Company updates report financial results, pipeline licensing activity and inducement awards under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals (Nasdaq: MIRM) will host an investor call on May 4, 2026 at 8:30 a.m. ET / 5:30 a.m. PT to share topline results from the VISTAS study of volixibat in patients with primary sclerosing cholangitis (PSC).
Access is by US toll-free and international phone numbers or via webcast on the company Investors website; an archived replay will be available.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report first quarter 2026 financial results and host a conference call on May 6, 2026 at 4:30 p.m. ET / 1:30 p.m. PT.
Dial-in numbers and an international line are provided; a live webcast and archived replay will be available via the Investors section of Mirum's website.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported that the Phase 2b portion of AZURE-1 met its primary composite endpoint at Week 24 for brelovitug in chronic hepatitis delta virus (HDV).
At Week 24, virologic response occurred in 100% (300 mg QW) and 75% (900 mg Q4W) versus 0% delayed; composite endpoint achieved in 45% and 35% versus 0%. Safety was described as favorable. Full Phase 2b results will be presented at EASL May 27-30, 2026; Phase 3 toplines expected H2 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement grants on April 10, 2026: non-qualified stock options to purchase 13,700 shares and 18,200 restricted stock units issued to 12 new employees under the 2020 Inducement Plan.
Each option has an exercise price of $95.20 (closing price on April 10, 2026). Options vest over four years (25% after one year, then monthly over 36 months). RSUs vest over three years (33% each anniversary). Awards are subject to plan and award agreement terms.
Mirum Pharmaceuticals (Nasdaq: MIRM) completed enrollment in EXPAND, a Phase 3 randomized, double-blind, placebo-controlled study evaluating LIVMARLI (maralixibat) for cholestatic pruritus in patients aged 6 months or older with rare cholestatic liver diseases, including biliary atresia.
The 20-week placebo-controlled portion randomizes patients to maralixibat 285 µg/kg twice daily or placebo; the primary endpoint is change in pruritus severity to Week 20. Topline data expected Q4 2026.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported inducement grants on March 11, 2026 under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee granted non-qualified stock options to purchase 5,400 shares and 6,800 RSUs to five new employees.
Options carry an exercise price of $91.75 (Mirum closing price on March 11, 2026). Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years (33% each anniversary). Awards are governed by Mirum’s 2020 Inducement Plan and award agreements, and are conditioned on continued service.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported completion of enrollment in Phase 3 AZURE-1 and completion of screening in Phase 3 AZURE-4 for brelovitug in chronic hepatitis delta virus (HDV).
Topline 24-week results from both studies are expected in 2H 2026; AZURE-1 and AZURE-4 will form the basis of a U.S. BLA filing with a potential U.S. launch in 2027. Brelovitug holds Breakthrough Therapy designation from the FDA.
Mirum Pharmaceuticals (Nasdaq: MIRM) reported 2025 net product sales of $521.3M and provided 2026 guidance of $630M–$650M in expected global net product sales. The company highlighted multiple near‑term registrational readouts in 2026 and recent regulatory approvals and an acquisition expanding its HDV program.
Key near‑term catalysts include VISTAS topline in PSC (Q2 2026), LIVMARLI EXPAND topline (Q4 2026), and AZURE HDV readouts in H2 2026. Cash and investments were $391.4M at year‑end 2025.
Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in multiple investor conferences in early March 2026, including TD Cowen (March 2), Citizens Life Sciences (March 10), Barclays Global Healthcare (March 10), and Leerink Partners (March 11).
Fireside chat times: March 2 at 1:10 p.m. ET, March 10 at 10:10 a.m. ET, and March 11 at 10:00 a.m. ET. The company said the sessions will be webcast live and available for replay in Mirum's Investors section.
Mirum Pharmaceuticals (Nasdaq: MIRM) will report fourth quarter and year‑end 2025 financial results on February 25, 2026. A conference call and webcast will follow to discuss results and recent corporate progress.
The live call is scheduled for 4:30 p.m. ET / 1:30 p.m. PT; dial‑in and webcast replay details are provided for investors.